Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Halozyme Therapeutics Q3 2026 Results: Net Income $247M, Up 41.0% YoY

Halozyme Therapeutics reported strong growth for the third quarter of 2026, with total revenues increasing to $493.0 million compared to $354.3 million in the prior year, driven primarily by higher royalty and product sales. Net income rose to $247.0 million, while the company significantly restructured its debt through the issuance of 2033 Convertible Notes and the repayment of 2027 and 2028 notes.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue493.0354.3
Profit before tax290.6219.0
Net income247.0175.2
EPS (diluted, $ a share)$2.01$1.43

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+41.0%
Revenue, year on year+39.2%
Operating margin59.8%
Source

10-Q filed with the SEC, NASDAQ: HALO. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Halozyme Therapeutics, Inc.: key numbers

Share price
$95.97Close, Nov 17
Market cap
$10.9B
Shares outstanding
114.01MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Halozyme Therapeutics, Inc.

All →
8:34 PM ET Form 4
Insider Selling

Halozyme Therapeutics President and CEO Helen Torley Sells $6M of Stock

Helen Torley, President and CEO, sold 60,000 shares of Halozyme Therapeutics, Inc. at $96.85 to $101.72 a share (average $100.01) in 10 transactions, worth $6M in total between Nov 12, 2026 and Nov 16, 2026. Shares held after the trade: 767,780 (-0.0%).

Value
$6M
Shares
60,000
Average price
$100.01
Role
President and CEO
Holding change
-0.0%
Trade date
Nov 12, 2026 to Nov 16, 2026
4:13 PM ET 8-K
Financial Results

Halozyme Therapeutics Financial Results

Halozyme Therapeutics reported record Q3 2026 financial results with total revenue increasing 39% year-over-year to $493 million, driven by a 44% surge in royalty revenue. Based on strong performance, the company raised its full-year 2026 guidance for revenue, adjusted EBITDA, and non-GAAP EPS while highlighting a legal victory in the Netherlands protecting its intellectual property against Merck.

Term
Q3 2026

“Halozyme delivered another exceptional quarter, with total revenue increasing 39% and royalty revenue growing 44% year-over-year to record levels.”

Dr. Helen Torley, President and Chief Executive Officer

“Based on our strong financial performance this quarter, we are pleased to be able to raise our guidance for the full year 2026.”

Darren Snellgrove, Executive Vice President and Chief Financial Officer
7:56 PM ET Form 4
Insider Selling

Halozyme Therapeutics President and CEO Helen Torley Sells $6.61M of Stock

Helen Torley, President and CEO, sold 60,000 shares of Halozyme Therapeutics, Inc. at $107.90 to $113.69 a share (average $110.18) in 12 transactions, worth $6.61M in total between Oct 6, 2026 and Oct 8, 2026. Shares held after the trade: 767,780 (-0.0%).

Value
$6.61M
Shares
60,000
Average price
$110.18
Role
President and CEO
Holding change
-0.0%
Trade date
Oct 6, 2026 to Oct 8, 2026
4:38 PM ET Form 4
Insider Selling

Halozyme Therapeutics Insider Matthew L. Posard Sells $568K of Stock

Matthew L. Posard sold 5,230 shares of Halozyme Therapeutics, Inc. at $107.17 to $110.04 a share (average $108.54) in 4 transactions, worth $568K in total on Oct 1, 2026. Shares held after the trade: 53,609 (-0.2%).

Value
$568K
Shares
5,230
Average price
$108.54
Holding change
-0.2%
Trade date
Oct 1, 2026
4:20 PM ET 8-K
Leadership Change

Halozyme Therapeutics Leadership Change

Halozyme Therapeutics appointed James Daly to its Board of Directors, effective September 28, 2026. Mr. Daly will serve in the class of directors with a term ending at the 2029 annual meeting and will receive standard compensation under the company's non-employee director program.

Counterparty
James Daly
4:41 PM ET 8-K
Loan & Debt

Halozyme Therapeutics $1.5B Debt Financing with The Bank of New York Mellon Trust Company, N.A.

Halozyme Therapeutics completed the sale of $1.5 billion in 1.50% Convertible Senior Notes due 2033, which included a $200 million overallotment option exercised by initial purchasers. The company used the proceeds to fund capped call transactions and to repurchase approximately $652.5 million of its existing 0.25% notes due 2027 and 1.00% notes due 2028.

Value
$1.5B
Counterparty
The Bank of New York Mellon Trust Company, N.A.
Term
through 2033

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.